GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe

GenSight Biologics to Present at Upcoming Industry and Investor Conferences

GenSight Biologics strengthens its management team to support the launch of LUMEVOQ® in Europe

GenSight Biologics Reports Interim Financial Results for the First Half of 2022

Cell UK by Oxford’s Global, London (UK) & Virtual

BIO-Europe 2021, Virtual

GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa

Mitochondrial Diseases Conference 2021 by Mitocon, Virtual

28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Virtual

2021 ARM Cell & Gene Meeting on the Mesa, Carlsbad, CA (USA) & Virtual